Mabion Third Quarter 2024 Earnings: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)
Mabion (WSE:MAB) Third Quarter 2024 Results
Key Financial Results
- Revenue: zł516.0k (down 98% from 3Q 2023).
- Net loss: zł16.3m (down by 250% from zł10.9m profit in 3Q 2023).
- zł1.01 loss per share (down from zł0.67 profit in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Mabion Earnings Insights
Looking ahead, revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%.
Performance of the market in Poland.
The company's shares are down 12% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Mabion (at least 1 which makes us a bit uncomfortable), and understanding these should be part of your investment process.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:MAB
Mabion
A biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland.
Flawless balance sheet slight.